Cargando…
Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs
The last three decades have seen the biotherapeutic drug market evolve from promising concept to market dominance in a range of clinical indications. This growth has been spurred by the success of established drug classes like monoclonal antibodies, but also by the introduction of biosimilars, and m...
Autores principales: | Vandivort, Tyler C., Horton, David B., Johnson, Steven B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057416/ https://www.ncbi.nlm.nih.gov/pubmed/33948231 http://dx.doi.org/10.1017/cts.2020.493 |
Ejemplares similares
-
Assessing the Immunogenicity of Biopharmaceuticals
por: Pineda, Carlos, et al.
Publicado: (2016) -
Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors
por: Klopfenstein, Mitchell, et al.
Publicado: (2015) -
10(th) European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
por: Tourdot, S., et al.
Publicado: (2020) -
Progress in biopharmaceutical development
por: Kesik‐Brodacka, Malgorzata
Publicado: (2017) -
The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)